Homepage Top Section1

Vitrakvi and BAY 2731954 are oncology compounds, which are being developed for the treatment of advanced solid tumors harboring NTRK gene fusions in adult and pediatric patient population.

Cenobamate is a novel and small molecule investigational antiepileptic drug being developed to treat partial-onset seizures in adult patients. Under exclusive licensing agreement, Arvelle will develop and commercialize

The company said that new data from three independent preclinical animal models of lung, kidney and liver fibrosis have yielded promising preclinical efficacy data for its ROCK2 compound.

Finch has designed CP101 therapeutic candidate for the prevention of recurrent C. difficile, which is a bacterial infection affecting more than 500,000 patients per year. The Centers for

Cablivi has been approved in combination with plasma exchange and immunosuppression to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is said to be the first FDA-approved

MEDI8897, which is a single dose extended half-life anti-RSV F monoclonal antibody (mAb), is being developed jointly by AstraZeneca’s biologics research and development arm MedImmune and Sanofi Pasteur.

The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based pharma

MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop,

The breakthrough therapy designation has been granted for V114 to prevent invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients aged between six weeks and